VTCN1 and neoplasm: It was reported that T cell function and augmented T cell mediated responses was successfully rescued in vivo, and the tumor burden reduced in a murine tumor model using anti-mouse B7-H4 antibodies, indicating proof of therapy for targeting B7-H4 in vitro [13, 15, 30].